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Abstract
Objective The goal of this study was to evaluate clinically
the acceptability of the IDAS II (Intelligent Drug Admin-
istration System), a new electronic device that enables drug
adherence monitoring.
Methods IDAS II was compared to another electronic
monitor, the Medication Event Monitoring System (MEMS)
in a randomised two-way cross-over study involving 24
hypertensive patients treated with irbesartan. Patients used
each device for 2 months. The main parameter of evaluation
was the patients’ opinion on both devices. Rates of
adherence and blood pressure were also assessed.
Results Most patients considered both devices to be reliable
reminders (IDAS II: 75%;MEMS: 84%, p = ns). Ten
patients (42%) preferred the MEMS, while 11 (46%)
preferred the IDAS II; three (12%) expressed no preference.
Patients found the MEMS device easier to use than the
IDAS device (p<0.001) but appreciated the IDAS blister
packs better than the MEMS bulk packaging (p<0.01).
Over the 4-month period, the median “taking adherence”
was excellent (99.2%) and comparable with both devices.
However, the regularity of drug intake timing was higher
with the IDAS II (p<0.01).
Conclusion IDAS II, a new electronic device enabling drug
adherence monitoring without reconditioning of the drugs
appears to be a well-accepted device. Overall, practicability
and acceptability of the IDAS II and the MEMS device
were similar. Thus, IDAS II could be a useful tool for the
management of long-term therapies.
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Introduction
Adherence to prescribed medications is a key factor in
disease management. However, low adherence to chronic
medications is frequent [1], and about one in four patients
do not adhere well to prescribed drug therapy [7]. The
World Health Organization (WHO) estimated that 50–70%
of patients in a general hypertensive population do not take
their antihypertensive medication as prescribed and de-
scribed poor adherence as one of “the most important cause
of uncontrolled blood pressure”. The WHO recognises the
importance of supporting chronic patients in increasing and
maintaining long-term drug adherence [14].
The detection and assessment of poor adherence is a
difficult and problematic task for healthcare professionals.
In clinical settings, questions directly addressed to patients
on their drug intake are the most practical means of
ascertainment, but this method is prone to inaccuracy
[10]. Patients usually tend to overestimate their adherence
due to difficulties recalling the details of their medication
taking or in attempts to please their physicians. Conse-
quently, physicians must frequently rely on their own
clinical judgement which, unfortunately, is often inaccurate
in terms of identifying poor adherers [3, 9].
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To date, the electronic monitoring system called MEMS
(Medication Event Monitoring System; AARDEX, Zug,
Switzerland) is the most reliable non-invasive method for
assessing patient adherence, [2, 4] and, thereby, assisting
healthcare professionals to make rational therapeutic deci-
sions [4]. Indeed, the MEMS device provides an accurate,
dynamic and “real time” follow-up of the patient’s pill-
taking behaviour [6, 13]. To our knowledge, very few other
reliable electronic monitoring devices are available in
clinical practice. However, the use of the MEMS device
requires reconditioning of the drugs from their original
packaging, a procedure which is time-consuming, costly
and not accepted in some countries.
Given the clinical importance of the drug adherence
issue, new, easy-to-use devices would be welcome. We
report here the results of a randomised crossover study in
which we evaluated the clinical acceptability of a new
electronic device for monitoring patient’s drug adherence –
the IDAS II (Intelligent Drug Administration System; Bang
and Olufsen Medicom, Denmark) and compared it to the
MEMS device.
Methods
Study design
This 4-month randomised (1:1) open cross-over study was
conducted at the Hypertension Outpatient Unit of the
University Hospital (CHUV) and the Pharmacy of the
University Outpatient Medical Clinic (PMU), Lausanne,
Switzerland. One pharmacist (VS) and two physicians (GW
and MB) were involved in the inclusion and follow-up of
the patients. The study protocol was approved by the local
ethics committee, and written informed consent was
obtained from all participating patients.
Patients were invited to participate if they met the
following inclusion criteria: (1) hypertensive patient cur-
rently treated with irbesartan 150 or 300 mg once a day, or
(2) newly diagnosed patient with hypertension on the point
of starting with irbesartan 150 or 300 mg daily and (3) an
understanding of French and the aim of the protocol.
Patients were prescribed irbesartan without any changes in
their regimen during the whole study. Additional treatments
were allowed during the study but were not monitored
electronically.
Study protocol and assessments
After inclusion in the study by physicians, patients were
referred to the pharmacist who dispensed, in a random
sequence, irbesartan in the MEMS 6 SmartCap device
(Table 1) or in the IDAS II device for a 2-month period. At
the end of the first 2 months, patients received the
alternative device for a second 2-month period. There was
no washout period. Randomisation was performed using a
computer-generated random-number table.
Patients were seen on three occasions: at a randomly
chosen time and at the end of each 2-month period. At
inclusion, patients were instructed on the correct use of the
electronic monitoring device in a interview with the
pharmacist who prepared and dispensed the devices. At
Table 1 Description of the
IDAS II and MEMS devices The IDAS I (Intelligent Drug Administration System, Bang
and Olufsen Medicom, Denmark) is an electronic device that
accommodates blister packs. An electric foil is fixed upon the
tablet slots. Each time a pill is taken, the electric foil is ruptured
which activates the recording of the date and hour at which
the drug was removed from the blister. This device has two
reminders: (1) one visual which indicates time elapsed since
the last dose and the actual time and (2) one audible which
sounds at chosen and fixed time for 1 min or until the patient
opens the device. The audible reminder can be deactivated
upon request.
The MEMS 6 SmartCap (Medication Event Monitoring System,
AARDEX, Zug, Switzerland) consists of a usual bulk pill
container fitted with a special cap, which contains a
microelectronic system that automatically records the date
and hour of each opening of the bottle and a LCD display on
top of the bottle. The LCD display indicates the number of
daily openings and the number of hours elapsed since
the last opening.
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the second visit, patients returned the device to the
pharmacy and filled in a questionnaire (Questionnaire 1)
assessing the acceptability and usefulness of the device.
This questionnaire assessed six items: (1) handling (easi-
ness), (2) LCD display information (understanding and
helpfulness), (3) reminder functions (understanding and
helpfulness), (4) subjective appreciation of impact on drug
intake, (5) patient satisfaction with the device and (6)
technical problems with the device. At the final visit,
patients once again filled in Questionnaire1 and were asked
in addition to fill in a second questionnaire. Questionnaire 2
assessed the following items: (1) overall patient’s prefer-
ences as well as specific preferences in handling, cumber-
some and packaging, (2) subjective appreciation of impact
on drug intake. Answers to Questionnaires 1 and 2 were
dichotomous (yes/no) or graduated on a four-point Likert
scale “from a lot” to “not at all” (0–4). The questionnaires
were developed specifically for this study, and understand-
ing was tested by four patients, one pharmacist and two
physicians before the study was initiated. At each visit, the
pharmacist downloaded the data from the electronic
monitor, printed out the adherence report (calendar and
chronology plot) and reviewed it with the patient.
Five indices were used to quantify drug adherence [10].
First, the percentage of doses taken was calculated as the
number of times the MEMS/IDAS II had been opened/
activated divided by the number of times the device should
have been opened/activated during the considered period.
Taking adherence was defined as the percentage of days
with correct dosing. Timing adherence was defined as the
percentage of correct intervals between two doses (an
interval was defined as being correct if it was located within
±25% of the prescribed interval). Drug holidays were
defined as no medication intake during a time period longer
than 24 h. The percentage of drug holidays is the number of
drugs holidays (expressed in days) divided by the number
of monitored days. In addition, we computed a timing
distribution index. To calculate this index, we identified the
hour at which the medication was taken most frequently
(mode of hour distribution). We then calculated the sum of
deviations from this mode, divided by the number of days
at which drug was taken using the following formula: DI ¼
Pn
i¼1
hih0j j
n
where h0 is the mode of distribution of the hour of
drug intake, hi is the hour of drug intake on day I and n is
the number of days at which drug was taken. Days when
drugs are not taken or taken twice were not counted. For
example, a patient took his/her medication 21 times at 7 a.
m., 4 times at 6 a.m., 3 times at 8 a.m. and 2 times at 9 a.m.
for 30 days. His mode is 7 a.m.. The timing distribution
index is: {[(7−7) × 21] + [(7−6) × 4] + [(8−7) × 3] + [(9−7) ×
2]}/30. A small distribution index means a regular timing of
drug intake.
Statistical analysis
Baseline characteristics were summarised as means (±SD)
or as percentages, as appropriate. Adherence indices were
compared using the Wilcoxon rank sum test. The answers
to Questionnaire 2 were compared using binomial proba-
bility test. Two-sided p values less than 0.05 were
considered to be statistically significant. Statistical analysis
was performed with STATA ver. 9.0 (STATA Corp, College
Station, TX).
Results
The baseline characteristics of the patients are shown in
Table 2. Three patients were newly treated with irbesartan.
Twenty-five patients were included in the study, but only 24
completed it. One patient withdrew from the IDAS II
period because he was unable to handle the device.
All patients were able to handle the MEMS device, and
98% of them were able to use the IDAS II device
appropriately. More than one third of the patients (9/24;
38%) indicated that pressing down on the tablets to get
them out of the special blister cards of the IDAS was
difficult; however, replacing the blister card with a new one
was easy for nearly all patients (23/24; 96%). One patient
experienced difficulties in opening the IDAS II, in releasing
the latches and in pressing down on the tablets to get them
out of the blister card. One patient did not use the IDAS II
correctly, and the device did not record the doses.
Table 2 Baseline characteristics of the patients (n=25)
Characteristics
Sex (men/women) 12/13
Mean age, years (range) 58.0 (35–75)
Mean systolic BP, mmHg (SD) 144.0 (24.8)
Mean diastolic BP, mmHg (SD) 85.9 (12.1)
Mean body mass index, kg/m2 (SD) 28 (5.4)
Monitored treatment
Ibesartan 150 mg/d qd 20
Ibesartan 300 mg/d qd 5
Additional antihypertensive drugs prescribed
Diuretics 11
Calcium antagonists 5
Beta-blockers 5
Number of antihypertensive therapies
Monotherapy 12
Bitherapy 7
Tritherapy or more 6
Mean number of antihypertensive drugs (range) 1.9 (1–4)
BP, Blood pressure; SD, standard deviation; qd, once a day
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No patient expressed problems reading the information
displayed on both devices. Most of the patients characterised
the display information of the IDAS II (21/24; 88%) and the
MEMS device (21/25; 84%) as “easy to understand”. The
answers differed in terms of the usefulness of the visual and
audible reminders. The MEMS LCD display information
indicating the number of doses taken during the present day
and the number of hours elapsed since the last opening were
considered to be useful by 64% (16/25) and 28% (7/25) of
the patients, respectively. The IDAS II digital display
indicating the time since last dose, the visual blinking
reminder and the audible reminder were considered to be
useful by 46% (11/24), 38% (9/24) and 42% (10/24) of
patients, respectively. Four patients asked the pharmacist to
deactivate the IDAS II audible reminder.
Patients reported two types of technical failures with the
IDAS device. First, the IDAS II had a higher incidence of
LCD display failures than the MEMS device (42 vs. 20%;
p=0.017). Secondly, one patient encountered troubles with
the IDAS audible reminder, which sometimes rang at the
wrong time although the settings were correct and the
pharmacist did not experience any technical problem in the
preparation and setting of both electronic devices. On
average, a total of 7 min (range 12–20 min) were required
to prepare the IDAS II device and 17 min (range 5–10 min)
to prepare the MEMS device (p<0.001). A total of 7 min
(range 5–10 min) was necessary for the MEMS’ initial
instruction session and 18 min (range 10–40 min) for the
IDAS II device (p<0.001).
In terms of drug intake, 14 patients with the MEMS
(56%) and 12 patients (50%) with the IDAS II reported that
the devices helped them maintain a more regular drug
intake. The assessment of patient satisfaction revealed that
the majority of the patients considered both electronic
devices to be a reliable reminder (84% with the MEMS vs.
75% with the IDAS II). Only two patients felt that they
were being "observed" too much with both devices. Two
patients (8%) did not take any interest in the MEMS device,
and three (12%) considered it to be useless. Eight patients
(33%) did not take any interest in the IDAS II device, and
eight (33%) considered it to be useless. Approximately half
of the patients expressed a willingness to use both devices
in the future.
Table 3 shows the comparison of both devices (Ques-
tionnaire 2). Patients’ preference in terms of handling
tended towards the MEMS device, but there was no
difference of opinion on the cumbersomeness of both
electronic devices. Patients preferred the blister pack (IDAS
II) to the bulk pill-container (MEMS) because of better
expected hygiene. More patients preferred the IDAS II as a
supporting device over the MEMS. However, nine patients
said that neither of the devices was of any help for the
Table 3 Results of Questionnaire 2: comparison of both devices
Questions MEMS IDAS II p valuea None Both No answer
Which device was easier to use? 17 (71) 5 (21) <0.001 0 (0) 2 (8) 0 (0)
Which device was less cumbersome? 11 (46) 10 (42) ns 1 (4) 2 (8) 0 (0)
Which drug presentation did you prefer?b 8 (35) 15 (63) <0.01 0 (0) 0 (0) 1 (4)
Which device supported your drug intake the most? 4 (17) 10 (42) <0.05 9 (37) 1 (4) 0 (0)
Which device did you prefer? 10 (42) 11 (46) ns 2 (8) 1 (4) 0 (0)
Values are numbers (percentages) of patients, unless stated otherwise
aMEMS vs. IDAS II (binomial probability test)
bMEMS, Bulk pill-container vs. IDAS II, blister pack
Table 4 Electronically
monitored drug adherence to
irbesartan 150 mg or 300 mg
once a day using the IDAS II
vs. MEMS device
ns, Not significant; range is
expressed as (minimum,
maximum)
2-month monitoring period
IDAS II (n=23) MEMS (n=25) p-value
Duration of monitoring (days) 62 63 −
Median (range) (48.0, 70.0) (47.0, 104.0)
Percentage of doses taken 100.0 100.0 ns
Median (range) (40.3, 100.0) (50.0, 101.8)
Taking adherence (%) 100.0 100.0 ns
Median (range) (40.3, 100.0) (50.0, 100.0)
Timing adherence (%) 96.7 97.2 ns
Median (range) (23.0, 100.0) (21.8, 100.0)
Distribution index (mean±SD) 0.60±0.55 1.03±0.68 <0.01
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simple reason that they already had a strong daily routine
for drug intake (i.e. teeth-brushing, mealtimes, walking the
dog and shaving). Patients did not show any significant
preference for one device or the other one.
Over the 4-month study, the adherence was very high
whatever the device, with a median taking adherence of
99.2% (range 62.7–100 %). During the first 2-month
period, the median taking adherence was 100% (range
40.3–100%), with only two patients having a taking
adherence <80%. During the last 2-month period, adher-
ence was still excellent, with a median taking adherence of
98.4% (range 84.1–100%) (Table 4). The median distribu-
tion index was lower with the IDAS II device, indicating
that the patients showed a stricter adherence to taking their
drug at the same time, day after day with the IDAS II than
with the MEMS device (Fig. 1).
Discussion
This study has evaluated the clinical acceptability of a new
electronic device, IDAS II. The results showed that
practicability and acceptability were similar with the IDAS
II and the MEMS devices, and the latter is now frequently
used in clinical studies. The patients appreciated the MEMS
device for its ease of handling and for the reminder function
indicating the number of doses taken during the present
day, but they appreciated the IDAS II device for drug
packaging in the form of the blister pack and the reminder
functions indicating the time since last dose. Both devices
were considered to be reliable reminders supporting drug
intake even though many patients had already established a
daily routine for their drug intake. Hence, overall rates of
adherence to the prescribed drug therapy was very high and
comparable with both devices.
Patients were satisfied with both devices. In our
experience this is a rather consistent finding as a positive
appreciation of electronic monitoring of drug adherence
was also found in another study conducted in epileptic
patients followed electronically for 8 months with electronic
devices [12]. The favourable appreciation by patients often
contrasts with the relative reluctance of physicians to use
these systems. In the present study, about half of the
patients expressed a willingness to use both devices in the
future, and half of them felt supported while being
monitored. Patient’s acceptation of any device depends on
the usefulness and suitability of the device but also on the
manner healthcare providers introduce it to the patient. It is
worthwhile noting that our patients were not selected to
participate in this study because they had drug adherence
problems. This may explain why about one third of them
did not really consider the devices to be useful.
The overall rates of adherence to the prescribed drug
therapy was very high in this study whatever the device.
This is well explained by the short duration of the
monitoring and probably by the motivation of patients
who accepted voluntarily to participate in the clinical study.
Moreover, both the pharmacist’s intervention and the
monitoring of drug adherence have been shown to enhance
the adherence to therapeutic regimens [4, 8, 12].
Patients tended to take their drug more regularly when
using the IDAS II. This is probably linked to the combined
visual and audible reminders of the device. Thus, the IDAS
II device might be of help for maintaining a regular timing
in patients who take drugs with a narrow therapeutic
window and who are supposed to take their medication
punctually every day. The audible reminder can be
deactivated upon the patient’s request; as such, the device
remains suitable for confidential circumstances.
One advantage of the IDAS II system is that drugs do
not need to be reconditioned and, therefore, they can be
used in their original blister pack. However, at the present
level of development of the device, this turned out to be a
limitation since the IDAS II device could only be used with
a one-size blister card. In this study, irbesartan had to be re-
packaged by the pharmaceutical company. In clinical
practice, the ideal electronic device should accept various
blister card sizes. Moreover, one device should ideally
enable the monitoring of different drugs simultaneously
since most chronic patients take several concomitant drugs.
Some patients found the IDAS II to be too large and not
practicable to take when travelling or to carry around in the
pocket. Nonetheless , the size of the IDAS II did not appear
to be a major limitation to its use.
In conclusion, our study shows that IDAS II, a new
electronic monitoring device of drug adherence, is well
accepted by patients and could represent a valuable device
for the clinical management of patients with chronic
diseases. The future development of electronic monitoring
devices such as the IDAS II is, in our view, an interesting and
important approach that assists physicians in diagnosing
drug adherence problems in some patients and supports
patient adherence in clinical practice.
Fig. 1 Timing distribution index with each device calculated as
indicated in the Methods section
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